These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 18238889

  • 1. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G.
    J Antimicrob Chemother; 2008 Apr; 61(4):919-24. PubMed ID: 18238889
    [Abstract] [Full Text] [Related]

  • 2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 3. Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
    Baiocchi L, De Leonardis F, Delle Monache M, Nosotti L, Conti RL, Lenci I, Carbone M, Di Paolo D, Cucchiarelli S, Angelico M.
    Antivir Ther; 2010 Jun; 15(4):633-9. PubMed ID: 20587856
    [Abstract] [Full Text] [Related]

  • 4. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [Abstract] [Full Text] [Related]

  • 5. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
    Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C.
    Antivir Ther; 2008 Jul; 13(4):607-11. PubMed ID: 18672540
    [Abstract] [Full Text] [Related]

  • 6. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 7. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
    Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaró J, Roget M, García I, Pedrol E, Tor J, Ballesteros AL, Salas A, Sirera G, Videla S, Clotet B, Tural C.
    Antivir Ther; 2006 Jan 02; 11(4):473-82. PubMed ID: 16856621
    [Abstract] [Full Text] [Related]

  • 8. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.
    J Antimicrob Chemother; 2007 Dec 02; 60(6):1347-54. PubMed ID: 17938129
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
    Merchante N, de los Santos-Gil I, Merino D, González-Serrano M, Mira JA, Sanz-Sanz J, Fernández-Fuertes E, Ruiz-Morales J, del Valle J, Macías J, Moro A, Pineda JA.
    J Hepatol; 2009 Apr 02; 50(4):684-92. PubMed ID: 19231001
    [Abstract] [Full Text] [Related]

  • 11. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.
    Antivir Ther; 2010 Apr 02; 15(2):267-79. PubMed ID: 20386082
    [Abstract] [Full Text] [Related]

  • 12. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B, CORAL-2 study group.
    Antivir Ther; 2011 Apr 02; 16(6):833-41. PubMed ID: 21900715
    [Abstract] [Full Text] [Related]

  • 13. Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
    Parruti G, Polilli E, Sozio F, Cento V, Pieri A, Di Masi F, Mercurio F, Tontodonati M, Mazzotta E, Ceccherini-Silberstein F, Manzoli L, Perno CF.
    Antiviral Res; 2010 Oct 02; 88(1):124-7. PubMed ID: 20708036
    [Abstract] [Full Text] [Related]

  • 14. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V, PRESCO Team.
    J Viral Hepat; 2008 May 02; 15(5):363-9. PubMed ID: 18179454
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, Rodríguez-Nóvoa S, Santos I, López-Cortes LF, Merino D, Rivero A, Soriano V.
    Antivir Ther; 2008 May 02; 13(3):429-37. PubMed ID: 18572756
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.
    New Microbiol; 2005 Jan 02; 28(1):13-21. PubMed ID: 15782622
    [Abstract] [Full Text] [Related]

  • 18. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.
    Ann Hepatol; 2013 Jan 02; 12(2):228-35. PubMed ID: 23396734
    [Abstract] [Full Text] [Related]

  • 19. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C.
    Ann Hepatol; 2010 Jan 02; 9(2):150-5. PubMed ID: 20526007
    [Abstract] [Full Text] [Related]

  • 20. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.
    J Viral Hepat; 2007 Jun 02; 14(6):387-91. PubMed ID: 17501758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.